Navigation Links
Osteotech Receives FDA Clearance for its Next Generation Grafting Material
Date:10/29/2008

EATONTOWN, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative healing, announced today that it has received 510(k) clearance from the United States Food and Drug Administration ("FDA") for its next generation grafting material. Osteotech received 510(k) clearance for this material as a bone graft substitute, and as a bone void filler, for use in the spine, pelvis and extremities.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "Receiving FDA clearance for our next generation grafting material is a great accomplishment for our team and another key milestone in our strategic plan. During our November 7, 2008 conference call, we will provide much more insight into this grafting material, its procedural uses and the timeline for introduction."

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, or this press release, please go to Osteotech's website at http://www.osteotech.com.

This press release may contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward- looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide ra
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
2. Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
3. Osteotechs Plexur M(TM) Biocomposite Receives FDA Clearance in Spine
4. Osteotechs Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine
5. Osteotech Posts First Quarter Earnings Per Share of $.05 on Revenue Growth of 10%
6. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
7. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
8. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
9. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
10. Osteotech to Present at the Sidoti Conference in New York
11. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Yonkers, NY (PRWEB) May 23, 2013 ... GRAPHALLOY® self-lubricating bushings mounted in stainless ... and self-lubricating properties of GRAPHALLOY with the application ... GRAPHALLOY Stainless Steel Pillow Blocks work exceptionally ... other corrosive or hostile liquids such as acids, ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... FL (PRWEB) May 23, 2013 On ... made trips to supermarkets to search for the growing ... store aisles. Results from a year long study were ... level in foods, specifically meats, over previous years. For ... how the growth of antibiotic resistant bacteria in food, ...
(Date:5/23/2013)... DIEGO , May 23, 2013  Verenium Corporation ... company focused on the development and commercialization of high-performance ... , Chief Financial Officer, will present at two upcoming ... Mr. Black will present at the Second Annual Marcum ... the Grand Hyatt Hotel in New York City.  The ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... 1:30 p.m. Eastern Time Today, GAITHERSBURG, Md., March ... financial results and corporate progress for,the full year ended ... we have further demonstrated that Iomai,s,vaccine and immunostimulant patches ... president and chief executive officer,of Iomai. "This lays the ...
... HILLS, Mass., March 6 Joseph F. Finn, ... of ActivBiotics, announced,today that the Office of Orphan ... has granted Orphan Drug Designation for M40403 for ... oral mucositis (OM),in cancer patients., The development ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... inflammatory diseases, today,reported results for the three months ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), For fiscal year ... 2006. For the year ended December 31, 2007, ...
Cached Biology Technology:Iomai Announces Year-End 2007 Financial Results and Business Progress 2Iomai Announces Year-End 2007 Financial Results and Business Progress 3Iomai Announces Year-End 2007 Financial Results and Business Progress 4Iomai Announces Year-End 2007 Financial Results and Business Progress 5Iomai Announces Year-End 2007 Financial Results and Business Progress 6ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer 2ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer 3EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 2EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 3EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 4EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 5
(Date:5/23/2013)... Frontiers in Plant Science , ... gene content and promoter evolution among grasses , ... of stretches of DNA that undergo little change in ... not code for any proteins. Some of these evolutionarily ... to regulate the expression of other genes or the ...
(Date:5/23/2013)... new mechanism by which estrogen suppresses lipid synthesis in ... new approach toward treating certain liver diseases. , ... they are changing long-held views in the field. Study ... journal Science Signaling . , "The dogma in ... that only receptors located in the nucleus respond to ...
(Date:5/23/2013)... medics have succeeded in treating cerebral palsy with autologous ... damage, a 2.5 year old boy had been in ... survival. Just two months after treatment with the cord ... the following months, the child learned to speak simple ... from a Korean study, dispel the long-held doubts about ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... assistant at the University of North Carolina Hospitals arrived ... a glowing track record in helping to repair heart ... perform gastric bypass operations for morbid obesity. , The ... Surgical System, manufactured by Intuitive Surgical. UNC currently is ...
... University of North Carolina Hospitals arrived in February sporting ... record in helping to repair heart valves, remove cancerous ... operations for morbid obesity. , The new arrival is ... by Intuitive Surgical. UNC currently is the only gynecological ...
... aquatic plants respond to plant disease and climate ... say plant pathologists with The American Phytopathological Society ... University, Ithaca, NY, many aquatic plants possess unique ... study, plant pathologists may be able to apply ...
Cached Biology News:FDA: 'Highly Unlikely' Green Tea Lowers Cancer Risk 2FDA: 'Highly Unlikely' Green Tea Lowers Cancer Risk 3Screen all at risk for HIV, plus pregnant women 2Screen all at risk for HIV, plus pregnant women 3
... Sepharose 4B, 10 ... purification of calmodulin-binding ... of calmodulin-regulated proteins ... cells. Category: Chromatography ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
... The PinPoint™ Vector Sequencing Primer is ... PinPoint™ Xa Vectors (Cat.# V2031, V2051, V2061). ... Xa site at nucleotides 325343, approximately 4050 ... region and can be used to determine ...
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
Biology Products: